Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of
children and 2% to 3% of adults. This guideline addresses important clinical questions that …

Atopic dermatitis is an inflammatory skin disease with early onset and with a lifetime
prevalence of approximately 20%. The aetiology of atopic dermatitis is unknown, but the …

This guideline was developed as a joint interdisciplinary European project, including
physicians from all relevant disciplines as well as patients. It is a consensus‐based …

Background Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging
pathogenic mediator in atopic dermatitis (AD). Objective We investigated the efficacy and …

Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can
affect all age groups. This evidence-based guideline addresses important clinical questions …

Atopic dermatitis is a common, chronic inflammatory dermatosis that can affect all age
groups. This evidence-based guideline addresses important clinical questions that arise in …

Background Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its
effectiveness and safety were demonstrated in clinical trials. Objective We sought to assess …

Transdermal drug delivery systems have been around for decades, and current
technologies (eg, patches, ointments, and creams) enhance the skin permeation of low …

Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of
children and 2% to 3% of adults. This guideline addresses important clinical questions that …

Background Many patients with moderate-to-severe atopic dermatitis (AD) require systemic
immunomodulating treatment to achieve adequate disease control. Objective We sought to …